Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00591123 · ClinicalTrials.gov registry record · Phase 2
Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia
A Phase 2 study of Unresectable Adenocarcinoma of the Esophagus and Metastatic Adenocarcinoma of the Esophagus, sponsored by Translational Oncology Research International.
- Completed
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
- 2
- Study locations
NCT00591123 is a Phase 2 study of Unresectable Adenocarcinoma of the Esophagus and Metastatic Adenocarcinoma of the Esophagus that has completed, run by Translational Oncology Research International. The registered enrollment target is 38 participants. The trial reports 2 study locations across 1 state.
The verdict
NCT00591123, a Phase 2 study of Unresectable Adenocarcinoma of the Esophagus and Metastatic Adenocarcinoma of the Esophagus, has completed, sponsored by Translational Oncology Research International.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
- 2
- Study locations
Study Summary
In this study, Erlotinib and 5-Fluorouracil (5-FU), Leucovorin and Oxaliplatin (a regimen known also as FOLFOX-6) will be the chemotherapy study drugs. The main purpose of this study is to test the safety and effectiveness of this combination of chemotherapy drugs and to see how they affect your cancer. Another purpose of this study is to examine samples from your blood and tumor. This research will be done to better understand how subjects respond to treatment. Specifically, researchers will look at the way your genes and proteins respond to drugs like those used in this study.
Conditions Studied
Interventions
- DRUG 5-FU
- DRUG FOLFOX
- DRUG Erlotinib
Study Locations (2)
California
- Translational Oncology Research International (TORI) Network - Los Angeles
- UCLA Jonsson Comprehensive Cancer Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2007-12 |
| Est. Completion | 2015-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00591123
The ClinicalTrials.gov registry entry for NCT00591123 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Translational Oncology Research International, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Unresectable Adenocarcinoma of the Esophagus appearing as the primary indexed condition, and to 3 interventions - of which 5-FU is the first listed.
NCT00591123 reports 2 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00591123 about?
NCT00591123 is a clinical study titled "Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia". In this study, Erlotinib and 5-Fluorouracil (5-FU), Leucovorin and Oxaliplatin (a regimen known also as FOLFOX-6) will be the chemotherapy study drugs. The main purpose of this study is to test the safety and effectiveness of this combination of chemotherapy drugs and to see how they affect your can...
What is the current status of trial NCT00591123?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2007-12. Estimated completion is 2015-09.
What conditions does trial NCT00591123 study?
This clinical trial studies the following conditions: Unresectable Adenocarcinoma of the Esophagus, Metastatic Adenocarcinoma of the Esophagus, Unresectable Adenocarcinoma of Gastric Cardia, Metastatic Adenocarcinoma of Gastric Cardia.
What interventions are being tested in trial NCT00591123?
The interventions under investigation include: 5-FU (DRUG), FOLFOX (DRUG), Erlotinib (DRUG).
Who is sponsoring clinical trial NCT00591123?
This trial is sponsored by Translational Oncology Research International, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00591123 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Unresectable Adenocarcinoma of the Esophagus
All registered trials for this condition
Metastatic Adenocarcinoma of the Esophagus
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.